Nationwide cohort study of bladder cancer patients in the Netherlands

Prospective Bladder Cancer Infrastructure: an Infrastructure for Observational and Interventional Bladder Cancer Research (ProBCI)

This study is trying to gather information from bladder cancer patients across the Netherlands to better understand how the disease progresses and how well different treatments work.

Quick facts

• Study type: Observational
• Enrollment: 3600 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Prospective Bladder Cancer Infrastructure Foundation (Academic / other)
• Locations: 23 sites ('s-Hertogenbosch and 22 other locations)
• Trial ID: NCT04503577 on ClinicalTrials.gov

What this trial studies

This study aims to create a prospective nationwide cohort of patients diagnosed with high-risk non-muscle-invasive, muscle-invasive, and metastatic bladder cancer in the Netherlands. It will involve collecting data from various medical centers to better understand the disease's progression and treatment outcomes. Patients aged 18 and older with bladder cancer at any stage except Ta will be included, and informed consent will be obtained from all participants. The study does not specify any interventions or treatments, focusing instead on observational data collection.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with bladder cancer at any stage except Ta.

Not a fit: Patients with Ta stage bladder cancer will not benefit from this study as they are excluded from participation.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into bladder cancer management and improve patient outcomes through better understanding of the disease.

How similar studies have performed: While this approach is observational and builds on existing knowledge, similar cohort studies have shown success in enhancing understanding of cancer progression and treatment.

Eligibility criteria

Inclusion Criteria:

* Bladder cancer
* Any stage except Ta
* 18 years or older
* Written informed consent

Exclusion Criteria:

* No exclusion criteria

Note: participation in ProBCI does not exclude the patient from participation in other studies.

Where this trial is running

's-Hertogenbosch and 22 other locations

• Jeroen Bosch Hospital — 's-Hertogenbosch, Netherlands (Recruiting)
• Zgt — Almelo, Netherlands (Recruiting)
• Meander Medical Center — Amersfoort, Netherlands (Recruiting)
• Amsterdam UMC, location VUMC — Amsterdam, Netherlands (Recruiting)
• Rijnstate — Arnhem, Netherlands (Recruiting)
• Amphia Ziekenhuis — Breda, Netherlands (Recruiting)
• Albert Schweitzer Hospital — Dordrecht, Netherlands (Recruiting)
• Ziekenhuis Gelderse Vallei — Ede, Netherlands (Recruiting)
• Treant Hospital — Emmen, Netherlands (Recruiting)
• University Medical Center Groningen — Groningen, Netherlands (Recruiting)
• Spaarne Gasthuis — Hoofddorp, Netherlands (Not_yet_recruiting)
• Medisch Centrum Leeuwarden — Leeuwarden, Netherlands (Recruiting)
• Alrijne Ziekenhuis — Leiderdorp, Netherlands (Recruiting)
• Maastricht University Medical Center — Maastricht, Netherlands (Recruiting)
• Canisius Wilhelmina Ziekenhuis — Nijmegen, Netherlands (Recruiting)
• Radboud univerisity Medical Center — Nijmegen, Netherlands (Recruiting)
• Erasmus Medical Center — Rotterdam, Netherlands (Recruiting)
• Zuyderland — Sittard, Netherlands (Recruiting)
• Elisabeth-TweeSteden Ziekenhuis — Tilburg, Netherlands (Recruiting)
• University Medical Center Utrecht — Utrecht, Netherlands (Recruiting)
• VieCuri — Venlo, Netherlands (Recruiting)
• SKB Winterswijk — Winterswijk, Netherlands (Recruiting)
• Isala — Zwolle, Netherlands (Recruiting)

Study contacts

• Study coordinator: A. Richters, PhD

Conditions Bladder Cancer; Bladder cancer; Prospective cohort